TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11469297

Group type: EXPERIMENTAL
Intervention: Gutta-percha points containing calcium hydroxide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aqueous calcium hydroxide suspension
Number of subjects: 120
Study: 9200808

Group type: EXPERIMENTAL
Intervention: Hobble restraint in the prone position
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hobble restraint in the upright position
Number of subjects: 6
Study: 8258267

Group type: EXPERIMENTAL
Intervention: TUDCA (Taurodeoxycholic acid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: UDCA (Ursodeoxycholic acid)
Number of subjects: 30
Study: 3979225

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon 1-21
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29528960

Group type: EXPERIMENTAL
Intervention: Full depth with 50% 1RM load
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Full depth with 85% 1RM load
Number of subjects: 19
Study: 30082719

Group type: EXPERIMENTAL
Intervention: Auditory streams structured in sets of 3 elements (tritones) during NREM sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory streams structured in statistical regularities during wake period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory streams randomly organized during NREM sleep
Number of subjects: 0
Study: 27310598

Group type: EXPERIMENTAL
Intervention: Unknown Loads (UL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Known Loads (KL)
Number of subjects: 28
Study: 24816938

Group type: EXPERIMENTAL
Intervention: Semiautomated volumetry (SaV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RECIST-based volumes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SaV and WHO-based relative changes in tumour volume
Number of subjects: 20
Study: 22286332

Group type: EXPERIMENTAL
Intervention: 8-week exercise program (n = 81)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (n = 79)
Number of subjects: 160
Study: 20623006

Group type: COMPARATOR
Intervention: Biometric assessment based on GDV technique (images without filter)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Biometric assessment based on GDV technique (images with filter)
Number of subjects: 48
Study: 18388097

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (500 mg every 8 hours for 49 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16024973

Group type: EXPERIMENTAL
Intervention: G/A or A/A genotypes
Number of subjects: 237

Group type: COMPARATOR
Intervention: G/G homozygotes
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: G/A and A/A patients
Number of subjects: 237
Study: 12694431

Group type: EXPERIMENTAL
Intervention: Novel low abrasive air-polishing powder
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hand instruments (positive control)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Negative control (untreated teeth)
Number of subjects: 27
Study: 10968308

Group type: EXPERIMENTAL
Intervention: Case management services
Number of subjects: 6409

Group type: EXPERIMENTAL
Intervention: Total payments for health care
Number of subjects: 6409
Study: 8667274

Group type: EXPERIMENTAL
Intervention: Glass ionomer luting cement (Ketac-Cem Maxicap)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zinc phosphate luting cement
Number of subjects: 60
Study: 1346082

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trimethaphan
Number of subjects: 100
Study: 3913379

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol + Prazosin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine + Prazosin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atenolol, Clonidine, Prazosin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prazosin + Clonidine
Number of subjects: 8
Study: 31246057

Group type: EXPERIMENTAL
Intervention: Emotion-focused therapy for trauma
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Emotional processes as predictors
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Increase in primary adaptive emotions from early to late treatment sessions
Number of subjects: 38
Study: 29901507

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 26457986

Group type: EXPERIMENTAL
Intervention: Fludarabine-plus-cyclophosphamide (FC)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777

Group type: COMPARATOR
Intervention: Fludarabine (not specified if alone or in combination)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Second-line therapy that induces a complete remission (CR)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: FC-based second-line therapy (including rituximab in 20%) or stem cell transplant
Number of subjects: 777
Study: 24489762

Group type: EXPERIMENTAL
Intervention: Dementia-care mapping (DCM)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 318
Study: 22158147

Group type: EXPERIMENTAL
Intervention: Vardenafil (VAR) 10 mg on demand
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched-placebo (PLB)
Number of subjects: 20
Study: 20332288

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for chronic pain
Number of subjects: 0
Study: 18053943

Group type: EXPERIMENTAL
Intervention: Low dose, 3 mg (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High dose, 10 mg (Group B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study: 16118370

Group type: EXPERIMENTAL
Intervention: Comprehensive school-based intervention
Number of subjects: 2744

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 2744
Study: 11448380

Group type: EXPERIMENTAL
Intervention: Postoperative biopsy specimens analyzed by histopathologist 1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative biopsy specimens analyzed by histopathologist 2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation of absence of esophageal mucosal inflammation with normalized pH monitoring
Number of subjects: 40
Study: 9924468

Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of local anaesthetic)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8044944

Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 301

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study: 2960296

Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Portal vein infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Crossover to hepatic arterial infusion after portal vein infusion
Number of subjects: 25
Study: 31715641

Group type: EXPERIMENTAL
Intervention: Alcohol-containing mouth rinse
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Xerostomia Inventory (XI)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Summated Xerostomia Inventory (SXI)
Number of subjects: 164
Study: 29255900

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 27352414

Group type: EXPERIMENTAL
Intervention: Pharmacist-staffed gout management program
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 77
Study: 24708338

Group type: EXPERIMENTAL
Intervention: Tunnel technique with subepithelial connective tissue graft (TUN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Coronally advanced flap with enamel matrix derivative (CAF)
Number of subjects: 24
Study: 23685914

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with releasable sutures
Number of subjects: 176

Group type: COMPARATOR
Intervention: Trabeculectomy without releasable sutures
Number of subjects: 176
Study: 21569996

Group type: EXPERIMENTAL
Intervention: Combination-therapy trastuzumab plus docetaxel (H+D)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sequential therapy of single-agent trastuzumab followed by docetaxel (H→D)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Monotherapy trastuzumab in H→D group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Subsequent docetaxel in H→D group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of trastuzumab treatment beyond progression
Number of subjects: 101
Study: 19485821

Group type: EXPERIMENTAL
Intervention: BPBM/GTR/PRP (experimental group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: BPBM/GTR (control group)
Number of subjects: 23
Study: 17049693

Group type: EXPERIMENTAL
Intervention: Leishmanization (LZ) with alum-precipitated autoclaved Leishmania major and BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leishmanization (LZ)
Number of subjects: 0
Study: 12771518

Group type: EXPERIMENTAL
Intervention: 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5‐fluorouracil (AV‐CMF)
Number of subjects: 263

Group type: COMPARATOR
Intervention: 6 cycles of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF)
Number of subjects: 263
Study: 11057795

Group type: EXPERIMENTAL
Intervention: Dopexamine at 0.5 microg/kg/min
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Dopexamine at 2.0 microg/kg/min
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Dopexamine (both doses)
Number of subjects: 412
Study: 9299913

Group type: EXPERIMENTAL
Intervention: Single question repeated 12 times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four different questions repeated 3 times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accumulating information across repetitions and physiological measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low motivation
Number of subjects: 0
Study: 8399607

Group type: EXPERIMENTAL
Intervention: Intraperitoneal vancomycin (1 g) and oral pefloxacin (400 mg b.i.d.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin (1 g) and gentamicin (80 mg loading dose, followed by 15 mg/2 L)
Number of subjects: 60
Study: 6576742

Group type: EXPERIMENTAL
Intervention: Wet aerosol salbutamol (10 mg, 4 x 0.5 ml of 0.5% standard solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metered dose inhaler (MDI) salbutamol (800 micrograms, 8 x 100 micrograms)
Number of subjects: 20
Study: 31104629

Group type: EXPERIMENTAL
Intervention: Monetary incentive of 2.00 for every maternal client attending postnatal care within 48 h of delivery (treatment group)
Number of subjects: 207

Group type: COMPARATOR
Intervention: No monetary incentive (control group)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Monetary incentive of 2.00 for every neonatal client attending postnatal care within 48 h of delivery (treatment group)
Number of subjects: 207
Study: 29348651

Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 27109132

Group type: EXPERIMENTAL
Intervention: Forest bathing trip
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban area (control)
Number of subjects: 0
Study: 24441968

Group type: EXPERIMENTAL
Intervention: Ecstasy users (n=18)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Controls (n=21)
Number of subjects: 45
Study: 22748591

Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 700

Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 700
Study: 20554464

Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 98

Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 98
Study: 18070468

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d and aspirin 100 mg/d plus cilostazol 200 mg/d
Number of subjects: 402

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d and aspirin 100 mg/d
Number of subjects: 402
Study: 16683408

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no tibolone)
Number of subjects: 94
Study: 14738775

Group type: EXPERIMENTAL
Intervention: Expected outcomes of operations (1 object + 1 tone = 2 objects and 1 object + 2 tones = 3 objects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unexpected outcomes of operations (1 object + 2 tones = 2 objects and 1 object + 1 tone = 3 objects)
Number of subjects: 0
Study: 10988282

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily for 1 week, then 50 mg twice daily for 5 weeks)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg daily) with Losartan
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg daily) with Captopril
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Captopril (with Indomethacin)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Losartan (with Indomethacin)
Number of subjects: 216
Study: 8989058

Group type: EXPERIMENTAL
Intervention: Local anesthesia (subcutaneous anesthetic infiltration)
Number of subjects: 270

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 270

Group type: COMPARATOR
Intervention: Venous puncture
Number of subjects: 270
Study: 1503330

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 101
Study: 6739139

Group type: EXPERIMENTAL
Intervention: Apalcillin 500 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Apalcillin 1000 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Apalcillin 2000 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Apalcillin 3000 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Apalcillin (all doses)
Number of subjects: 26
Study: 31721275

Group type: EXPERIMENTAL
Intervention: Deaf and Hard-of-Hearing college students
Number of subjects: 12056

Group type: COMPARATOR
Intervention: Hearing college students
Number of subjects: 12056
Study: 31317029

Group type: EXPERIMENTAL
Intervention: Lycopene 7 mg daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lycopene 30 mg daily (formulation 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lycopene 30 mg daily (formulation 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC) with 7 mg lycopene
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 30
Study: 28011328

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PVI + complex electrogram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PVI + linear ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sinus rhythm (SR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AF termination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolongation of AF cycle length (AFCL)
Number of subjects: 0
Study: 26140823

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for SAD
Number of subjects: 86
Study: 23223345

Group type: EXPERIMENTAL
Intervention: UNSAT diet (unsaturated fat-rich diet)
Number of subjects: 164

Group type: COMPARATOR
Intervention: CARB diet (carbohydrate-rich diet)
Number of subjects: 164

Group type: COMPARATOR
Intervention: PROT diet (protein-rich diet)
Number of subjects: 164
Study: 21850574

Group type: EXPERIMENTAL
Intervention: Safinamide 300 mg administered once daily under fasting conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tyramine 200 mg administered alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tyramine 50 mg and 100 mg administered on days 5, 6, and 7 respectively
Number of subjects: 20
Study: 20015429

Group type: EXPERIMENTAL
Intervention: Tunnel thread‐drawing method
Number of subjects: 244

Group type: COMPARATOR
Intervention: Classical therapy of thread‐drawing method (control)
Number of subjects: 244
Study: 16709702

Group type: EXPERIMENTAL
Intervention: Continuous noise combined with impulse noise
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Shift work
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Physical workload
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Exposure to two risk factors
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Exposure to all three risk factors
Number of subjects: 1804
Study: 12857474

Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) + Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Basic Treatment
Number of subjects: 47
Study: 10960753

Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: non-rinse conditioner (NRC, Dentsply DeTrey)
Number of subjects: 30

Group type: COMPARATOR
Intervention: no conditioning
Number of subjects: 30
Study: 8969720

Group type: EXPERIMENTAL
Intervention: External nasal dilator (Breathe Right Nasal Strips)
Number of subjects: 20
Study: 1451897

Group type: EXPERIMENTAL
Intervention: Uterine activity monitoring with findings revealed to clinicians (study group, n=9)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Uterine activity monitoring with findings not revealed to clinicians (control group, n=10)
Number of subjects: 58
Study: 6748924

Group type: EXPERIMENTAL
Intervention: Phosphate loading
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30650322

Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg single dose)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Primaquine (15 mg once daily for 14 days)
Number of subjects: 522
Study: 30304106

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Saxagliptin 5 mg
Number of subjects: 355
Study: 26935578

Group type: EXPERIMENTAL
Intervention: Cilengitide (2000 mg IV twice weekly) with metronomic temozolomide (60 mg/m²) and procarbazine (50 or 100 mg)
Number of subjects: 29
Study: 25044247

Group type: EXPERIMENTAL
Intervention: Training on approximate arithmetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numerical comparison
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numerical matching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visuo-spatial short-term memory
Number of subjects: 0
Study: 22853980

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)) plus Ramucirumab (10 mg/kg)
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m(2)) plus Placebo
Number of subjects: 1242
Study: 19853947

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 11618
Study: 17409312

Group type: EXPERIMENTAL
Intervention: Agalsidase beta, 1 mg/kg biweekly for up to 54 months
Number of subjects: 58
Study: 15365746

Group type: EXPERIMENTAL
Intervention: Group A (24 probands)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group B (24 probands)
Number of subjects: 48
Study: 11232671

Group type: EXPERIMENTAL
Intervention: Balloon dilation (18-mm through-the-scope balloon)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 83
Study: 9756423

Group type: EXPERIMENTAL
Intervention: Doppler method for brachial systolic blood pressure measurement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Auscultatory method for brachial systolic blood pressure measurement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oscillometric method for brachial systolic blood pressure measurement
Number of subjects: 50
Study: 8091825

Group type: EXPERIMENTAL
Intervention: Dobutamine with simultaneous volume loading (by CVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catecholamines (dobutamine and adrenaline)
Number of subjects: 0
Study: 3421071

Group type: EXPERIMENTAL
Intervention: Rydell four-flanged hook nail
Number of subjects: 223

Group type: COMPARATOR
Intervention: Gouffon pins
Number of subjects: 223
Study: 29649631

Group type: EXPERIMENTAL
Intervention: Multifactorial behavioral and medication management intervention delivered via telephone, including up to 36 monthly educational modules, home blood pressure monitoring, and electronic medication management recommendations.
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 281
Study: 28128646

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 40
Study: 26516434

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Cyclogest)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intramuscular progesterone (17‐α hydroxyprogesterone caproate)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 78
Study: 24081245

Group type: EXPERIMENTAL
Intervention: Triple therapy (prednisone, azathioprine, N-acetylcysteine)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 20851818

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no mBMCs)
Number of subjects: 100
Study: 18310647

Group type: EXPERIMENTAL
Intervention: Tailored messages to prepare families for withdrawal of life support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 16503543

Group type: EXPERIMENTAL
Intervention: Sufentanil intravenous analgesia (1 microg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl intravenous analgesia (10 microg/ml)
Number of subjects: 60
Study: 14623813

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 468